Dasatinib

In a recent American Heart Association scientific statement, a committee provided an overview of drug-to-drug interactions between cancer drugs and commonly used CV medications.

Combining the tyrosine kinase inhibitor dasatinib with prednisone and blinatumomab seemed safe in older patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, researchers reported.

Discontinuation of tyrosine kinase inhibitors after 3 years of use appeared safe for adults with chronic myeloid leukemia who achieved a sustained deep molecular response, according to results of the LAST study published in JAMA Oncology.

A chemotherapy-free first-line treatment strategy led to high rates of molecular response and survival among a subset of adults with acute lymphoblastic leukemia, according to study results published in The New England Journal of Medicine.

Discontinuation of first-line dasatinib after 3 years of treatment appeared safe among a cohort of patients with chronic myeloid leukemia who had achieved a sustained deep molecular response, according to results of the single-arm, multicenter, phase 2 DADI trial published in The Lancet Haematology.

Dasatinib appeared more effective than imatinib mesylate for treatment of children with Philadelphia chromosome-positive acute lymphoblastic leukemia, according to results of a randomized phase 3 clinical trial published in JAMA Oncology.

Chimeric antigen receptor T-cell therapy has proven to be a life-changing development for those with advanced, treatment refractory leukemia and lymphoma for whom other therapies have proven ineffective. But if we apply Newton’s law of motion to medicine, when CAR T-cell therapy effectively targets and kills cancer cells, an opposite reaction from the immune system causes treatment related-toxicities that can endanger the life of patients.